Wuhan Healthgen Biotechnology Corp. (SHA:688765)

Market Cap	13.08B
Revenue (ttm)	23.39M -3.6%
Net Income	-160.81M
EPS	-0.59
Shares Out	357.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,951,350
Open	36.78
Previous Close	36.73
Day's Range	36.49 - 37.49
52-Week Range	32.61 - 132.03
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 8, 2026

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 215
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688765

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 5, 2026

Data Sources Report a data error